154 related articles for article (PubMed ID: 35084182)
1. Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.
Zhao T; Zhang J; Tao Y; Liao H; Zhao F; Liang R; Shi X; Zhang Z; Ji J; Wu T; Pang J; Liu X; Zhan P
J Med Chem; 2022 Mar; 65(5):4218-4237. PubMed ID: 35084182
[TBL] [Abstract][Full Text] [Related]
2. Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
Zhao T; Meng Q; Sun Z; Chen Y; Ai W; Zhao Z; Kang D; Dong Y; Liang R; Wu T; Pang J; Liu X; Zhan P
J Med Chem; 2020 Oct; 63(19):10829-10854. PubMed ID: 32897699
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.
Shi X; Zhao T; Wang S; Xu S; Liao H; Gao S; Gao Z; Zhang J; Qi D; Zhang Z; Zheng F; Wang Y; Wang Z; Yang M; Yang Q; Yi F; Pang J; Liu X; Zhan P
J Med Chem; 2024 Mar; 67(6):5032-5052. PubMed ID: 38482820
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.
Zhang J; Dong Y; Gao S; Zhang X; Liao H; Shi X; Zhang Z; Zhao T; Liang R; Qi D; Wu T; Pang J; Liu X; Zhan P
Eur J Med Chem; 2022 Dec; 244():114816. PubMed ID: 36219903
[TBL] [Abstract][Full Text] [Related]
5. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Zhao Z; Liu J; Yuan L; Yang Z; Kuang P; Liao H; Luo J; Feng H; Zheng F; Chen Y; Wu T; Guo J; Cao Y; Yang Y; Lin C; Zhang Q; Chen J; Pang J
Eur J Med Chem; 2022 Nov; 242():114682. PubMed ID: 36001935
[TBL] [Abstract][Full Text] [Related]
9. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
10. Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.
Zheng F; Mai S; Cen X; Zhao P; Ye W; Ke J; Lin S; Hu H; Guo Z; Zhang S; Liao H; Wu T; Tian Y; Zhang Q; Pang J; Zhao Z
Bioorg Chem; 2024 Jun; 147():107381. PubMed ID: 38669781
[TBL] [Abstract][Full Text] [Related]
11. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
Dong Y; Zhao T; Ai W; Zalloum WA; Kang D; Wu T; Liu X; Zhan P
Expert Opin Ther Pat; 2019 Nov; 29(11):871-879. PubMed ID: 31593642
[No Abstract] [Full Text] [Related]
12. Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.
Li S; Liao H; Luo L; Meng B; Zheng F; Sheng L; Zhao H; Huan Y; Lei L; Zhai J; Zhao K; Tian J; Wu T; Li G; Pang J; Huang H
Eur J Med Chem; 2024 Apr; 269():116327. PubMed ID: 38547733
[TBL] [Abstract][Full Text] [Related]
13. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
Hou Z; Ma A; Mao J; Song D; Zhao X
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Tan PK; Liu S; Gunic E; Miner JN
Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors.
Hou X; Wang Y; Yang Y; Xiao Z
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959834
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout.
Wu JW; Yin L; Liu YQ; Zhang H; Xie YF; Wang RL; Zhao GL
Bioorg Med Chem Lett; 2019 Feb; 29(3):383-388. PubMed ID: 30579795
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
[TBL] [Abstract][Full Text] [Related]
18. Hypouricemic Effects of Extracts from
Han S; Wei R; Han D; Zhu J; Luo W; Ao W; Zhong G
Biomed Res Int; 2020; 2020():2968135. PubMed ID: 32083126
[No Abstract] [Full Text] [Related]
19. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
[TBL] [Abstract][Full Text] [Related]
20. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
Shi X; Zhao T; da Silva-Júnior EF; Zhang J; Xu S; Gao S; Liu X; Zhan P
Expert Opin Ther Pat; 2022 Dec; 32(12):1175-1184. PubMed ID: 36625031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
